Generation Bio (GBIO) Competitors $6.45 +0.17 (+2.71%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$6.54 +0.09 (+1.32%) As of 08/22/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GBIO vs. CYBN, ACTU, NKTX, NVCT, BIOA, GLSI, CRDF, DERM, CLLS, and MEIPShould you be buying Generation Bio stock or one of its competitors? The main competitors of Generation Bio include Cybin (CYBN), Actuate Therapeutics (ACTU), Nkarta (NKTX), Nuvectis Pharma (NVCT), BioAge Labs (BIOA), Greenwich LifeSciences (GLSI), Cardiff Oncology (CRDF), Journey Medical (DERM), Cellectis (CLLS), and MEI Pharma (MEIP). These companies are all part of the "pharmaceutical products" industry. Generation Bio vs. Its Competitors Cybin Actuate Therapeutics Nkarta Nuvectis Pharma BioAge Labs Greenwich LifeSciences Cardiff Oncology Journey Medical Cellectis MEI Pharma Generation Bio (NASDAQ:GBIO) and Cybin (NYSE:CYBN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability. Does the media prefer GBIO or CYBN? In the previous week, Cybin had 14 more articles in the media than Generation Bio. MarketBeat recorded 18 mentions for Cybin and 4 mentions for Generation Bio. Cybin's average media sentiment score of 0.01 beat Generation Bio's score of -0.17 indicating that Cybin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generation Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cybin 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in GBIO or CYBN? 95.2% of Generation Bio shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 21.8% of Generation Bio shares are owned by company insiders. Comparatively, 15.0% of Cybin shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has higher earnings and valuation, GBIO or CYBN? Cybin has lower revenue, but higher earnings than Generation Bio. Cybin is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeneration Bio$19.89M2.19-$131.67M-$10.82-0.60CybinN/AN/A-$57.88M-$4.60-1.55 Which has more risk and volatility, GBIO or CYBN? Generation Bio has a beta of 2.67, suggesting that its share price is 167% more volatile than the S&P 500. Comparatively, Cybin has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Do analysts recommend GBIO or CYBN? Generation Bio currently has a consensus price target of $10.67, indicating a potential upside of 65.37%. Cybin has a consensus price target of $85.00, indicating a potential upside of 1,088.81%. Given Cybin's stronger consensus rating and higher possible upside, analysts plainly believe Cybin is more favorable than Generation Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Generation Bio 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Is GBIO or CYBN more profitable? Cybin has a net margin of 0.00% compared to Generation Bio's net margin of -341.12%. Cybin's return on equity of -37.58% beat Generation Bio's return on equity.Company Net Margins Return on Equity Return on Assets Generation Bio-341.12% -91.07% -33.65% Cybin N/A -37.58%-36.59% SummaryCybin beats Generation Bio on 10 of the 16 factors compared between the two stocks. Get Generation Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GBIO vs. The Competition Export to ExcelMetricGeneration BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.44M$3.12B$5.83B$9.78BDividend YieldN/A2.23%4.40%4.05%P/E Ratio-0.6021.0031.3026.05Price / Sales2.19355.64454.60117.80Price / CashN/A44.5038.0259.36Price / Book0.808.129.536.60Net Income-$131.67M-$54.72M$3.26B$265.65M7 Day Performance2.54%2.62%2.14%2.01%1 Month Performance48.96%2.68%2.81%-0.33%1 Year Performance-75.66%10.93%30.70%19.04% Generation Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GBIOGeneration Bio3.1924 of 5 stars$6.45+2.7%$10.67+65.4%-74.4%$43.44M$19.89M-0.60150CYBNCybin2.4338 of 5 stars$6.92-2.0%$85.00+1,128.3%N/A$166.55MN/A-1.5850News CoverageAnalyst RevisionACTUActuate TherapeuticsN/A$8.25+1.6%$20.50+148.5%+3.9%$166.22MN/A0.0010News CoverageAnalyst DowngradeAnalyst RevisionNKTXNkarta2.0141 of 5 stars$2.35+0.9%$13.60+478.7%-54.0%$165.49MN/A-1.59140NVCTNuvectis Pharma3.722 of 5 stars$6.45+0.3%$15.33+137.7%-4.6%$163.69MN/A-5.518Positive NewsBIOABioAge LabsN/A$4.52-0.7%N/AN/A$163.12M$3.86M0.00N/AGLSIGreenwich LifeSciences1.6849 of 5 stars$12.01-1.3%$39.00+224.7%-13.9%$162.69MN/A-8.833Trending NewsAnalyst ForecastAnalyst RevisionCRDFCardiff Oncology1.5818 of 5 stars$2.43-0.4%$10.10+315.6%+1.3%$162.32M$680K-2.7920DERMJourney Medical1.6232 of 5 stars$7.00+0.7%$10.83+54.8%+65.6%$161.91M$56.13M-18.4290CLLSCellectis3.3966 of 5 stars$2.90+1.8%$4.00+37.9%+22.8%$158.41M$49.22M-3.54290Positive NewsShort Interest ↓MEIPMEI Pharma1.3271 of 5 stars$4.88-0.2%N/A+58.8%$158.28M$65.30M-1.03100News CoverageAnalyst Upgrade Related Companies and Tools Related Companies CYBN Alternatives ACTU Alternatives NKTX Alternatives NVCT Alternatives BIOA Alternatives GLSI Alternatives CRDF Alternatives DERM Alternatives CLLS Alternatives MEIP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GBIO) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Generation Bio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Generation Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access